| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1068965485 |
| P356 | DOI | 10.2119/MOLMED.2011.00444 |
| P932 | PMC publication ID | 3409282 |
| P698 | PubMed publication ID | 22549112 |
| P5875 | ResearchGate publication ID | 224878325 |
| P2093 | author name string | Chao Cheng | |
| Fang Wang | |||
| Zhenguo Liu | |||
| Li-wu Fu | |||
| Xing-ping Wu | |||
| Yong-ju Liang | |||
| Kenneth Kin Wah To | |||
| Shu-peng Chen | |||
| Xing-Gui Chen | |||
| Yan-jun Mi | |||
| P2860 | cites work | The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2) | Q73777786 |
| Bryostatin-I: an antineoplastic treasure from the deep? | Q78515761 | ||
| Signaling pathways governing tumor angiogenesis | Q37972805 | ||
| Colorectal cancer stem cells | Q37974613 | ||
| ERK activation by thymosin-beta-4 (TB4) overexpression induces paclitaxel-resistance | Q38510908 | ||
| Blockade of Her2/neu binding to Hsp90 by emodin azide methyl anthraquinone derivative induces proteasomal degradation of Her2/neu | Q39495900 | ||
| Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export. | Q39813507 | ||
| Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters | Q39854362 | ||
| Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. | Q39881351 | ||
| Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. | Q39916513 | ||
| Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol | Q40036920 | ||
| Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo | Q40284993 | ||
| Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo | Q40345597 | ||
| Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. | Q40410062 | ||
| Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. | Q40453744 | ||
| Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318. | Q40530013 | ||
| Efflux kinetics and intracellular distribution of daunorubicin are not affected by major vault protein/lung resistance-related protein (vault) expression | Q40534870 | ||
| A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance | Q40737960 | ||
| Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. | Q40904151 | ||
| Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. | Q40985808 | ||
| Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells | Q42833544 | ||
| Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study | Q43679835 | ||
| Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. | Q43739398 | ||
| Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. | Q44245530 | ||
| HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. | Q44450066 | ||
| Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance | Q44687014 | ||
| Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. | Q45930096 | ||
| Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. | Q45947457 | ||
| A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance | Q22008526 | ||
| A multidrug resistance transporter from human MCF-7 breast cancer cells | Q22008574 | ||
| Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor | Q24594930 | ||
| The human ATP-binding cassette (ABC) transporter superfamily | Q28204495 | ||
| Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study | Q28282189 | ||
| Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells | Q28302950 | ||
| Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene | Q30724183 | ||
| Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes | Q31932176 | ||
| Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) | Q33194199 | ||
| Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. | Q33194953 | ||
| Characterization of a side population of cancer cells from human gastrointestinal system | Q33225639 | ||
| Anthracenedione derivative 1403P-3 induces apoptosis in KB and KBv200 cells via reactive oxygen species-independent mitochondrial pathway and death receptor pathway | Q33296974 | ||
| ABCG2 is required to control the sonic hedgehog pathway in side population cells with stem-like properties. | Q33966214 | ||
| Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. | Q34135435 | ||
| Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo | Q34156054 | ||
| Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study | Q34584163 | ||
| Activation of the PI3K/Akt pathway and chemotherapeutic resistance | Q35046899 | ||
| Right on target: eradicating leukemic stem cells | Q35132225 | ||
| MET and VEGF: synergistic targets in castration-resistant prostate cancer | Q35575488 | ||
| Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy | Q35719811 | ||
| The biology of cancer stem cells and its clinical implication in hepatocellular carcinoma | Q35778321 | ||
| mTOR regulates cell survival after etoposide treatment in primary AML cells | Q35848196 | ||
| Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. | Q36536479 | ||
| Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies | Q36737772 | ||
| Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study | Q36877022 | ||
| Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. | Q36894740 | ||
| Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors | Q37078093 | ||
| Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2 | Q37119716 | ||
| Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. | Q37179139 | ||
| Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor | Q37624473 | ||
| Axitinib (AG-013736). | Q37674170 | ||
| ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy | Q37693265 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| axitinib | Q4830631 | ||
| P304 | page(s) | 887-898 | |
| P577 | publication date | 2012-07-18 | |
| P1433 | published in | Molecular Medicine | Q6895961 |
| P1476 | title | Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2. | |
| P478 | volume | 18 |
| Q88721921 | Antitumor effect of axitinib combined with dopamine and PK-PD modeling in the treatment of human breast cancer xenograft |
| Q28485188 | BIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cells |
| Q26747144 | Cancer stem cells (CSCs), cervical CSCs and targeted therapies |
| Q37707577 | Degradation of P-glycoprotein by pristimerin contributes to overcoming ABCB1-mediated chemotherapeutic drug resistance in vitro |
| Q36241043 | Functional significance of CD105-positive cells in papillary renal cell carcinoma. |
| Q32186144 | Kinetic Modeling of ABCG2 Transporter Heterogeneity: A Quantitative, Single-Cell Analysis of the Side Population Assay |
| Q39013427 | Nilotinib enhances the efficacy of conventional chemotherapeutic drugs in CD34⁺CD38⁻ stem cells and ABC transporter overexpressing leukemia cells |
| Q27693185 | Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors |
| Q35978108 | Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer |
| Q90274971 | Reversal of ABCB1-related multidrug resistance by ERK5-IN-1 |
| Q96304537 | Rociletinib (CO-1686) enhanced the efficacy of chemotherapeutic agents in ABCG2-overexpressing cancer cells in vitro and in vivo |
| Q86905514 | Silencing stem cell factor attenuates stemness and inhibits migration of cancer stem cells derived from Lewis lung carcinoma cells |
| Q37702375 | TRIM28 multi-domain protein regulates cancer stem cell population in breast tumor development. |
| Q49888021 | Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells. |
| Q36702964 | Zuo Jin Wan, a Traditional Chinese Herbal Formula, Reverses P-gp-Mediated MDR In Vitro and In Vivo |
Search more.